Effect of Transdermal Electromotive Drug Therapy on Fibrogenic Cytokine Expression in Peyronie's Disease

Urology

Volumn 74, Issue 3, 2009, Pages 566-570

  Stancik, Igor ^a   Schäfer, Romana ^b   Andrukhova, Olena ^c   Oeser, Reinhard ^d   Plas, Eugen ^a   Pflüger, Heinz ^a  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Medical University of Vienna   (Austria)

^d Oeser Ltd   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; LIDOCAINE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; VERAPAMIL;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG THERAPY; ELECTROMOTIVE DRUG THERAPY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PEYRONIE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUNICA ALBUGINEA; WESTERN BLOTTING;

ELECTROCHEMOTHERAPY; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED; PENILE INDURATION; RNA; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 69249221316     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.03.017     Document Type: Article

References (29)

1. Mulhall J.P., Creech S.D., Boorjian S.A., et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 171 6 Pt 1 (2004) 2350-2353
2. La Pera G., Pescatori E.S., Calabrese M., et al. Peyronie's disease: prevalence and association with cigarette smoking: a multicenter population-based study in men aged 50-69 years. Eur Urol 40 (2001) 525-530
3. Schwarzer U., Sommer F., Klotz T., et al. The prevalence of Peyronie's disease: results of a large survey. BJU Int 88 (2001) 727-730
4. Devine Jr. C.J., Somers K.D., Jordan S.G., et al. Proposal: trauma as the cause of the Peyronie's lesion. J Urol 157 (1997) 285-290
5. El Sakka A.I., Hassoba H.M., Pillarisetty R.J., et al. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression 16. J Urol 158 (1997) 1391-1394
6. Haag S.M., Hauck E.W., Szardening-Kirchner C., et al. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 51 (2007) 255-261
7. Mulhall J.P., Thom J., Lubrano T., et al. Basic fibroblast growth factor expression in Peyronie's disease. J Urol 165 (2001) 419-423
8. Riedl C.R., Plas E., Engelhardt P., et al. Iontophoresis for treatment of Peyronie's disease. J Urol 163 (2000) 95-99
9. Schafer R., Abraham D., Paulus P., et al. Impaired VE-cadherin/beta-catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy. Circulation 108 (2003) 1585-1591
10. Edgington E., Onghena P., Balakrishnan N., et al. Randomization Tests. Statistics: A Series of Textbooks and Monographs. 4th ed. (2007), Chapman & Hall/CRC, Boca Raton, FL
11. Brock G., Hsu G.L., Nunes L., et al. The anatomy of the tunica albuginea in the normal penis and Peyronie's disease. J Urol 157 (1997) 276-281
12. Davis Jr. C.J. The microscopic pathology of Peyronie's disease. J Urol 157 (1997) 282-284
13. Akkus E., Carrier S., Baba K., et al. Structural alterations in the tunica albuginea of the penis: impact of Peyronie's disease, ageing and impotence. Br J Urol 79 (1997) 47-53
14. Somers K.D., and Dawson D.M. Fibrin deposition in Peyronie's disease plaque. J Urol 157 (1997) 311-315
15. Diegelmann R.F. Cellular and biochemical aspects of normal and abnormal wound healing: an overview. J Urol 157 (1997) 298-302
16. Vande W.L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol 157 (1997) 306-310
17. Border W.A., and Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 90 (1992) 1-7
18. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
19. Moreland R.B. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 10 (1998) 113-120
20. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 171 (2004) 1605-1608
21. Di Stasi S.M., Giannantoni A., Capelli G., et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 91 (2003) 825-829
22. Montorsi F., Salonia A., Guazzoni G., et al. Transdermal electromotive multidrug administration for Peyronie's disease: preliminary results. J Androl 21 (2000) 85-90
23. El Sakka A.I., Hassoba H.M., Chui R.M., et al. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression 15. J Urol 158 (1997) 2284-2290
24. Davila H.H., Ferrini M.G., Rajfer J., et al. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 91 (2003) 830-838
25. Bruce A. Molecular Biology of the Cell (2002), Garland Science, London, UK
26. Massague J., and Chen Y.G. Controlling TGF-beta signaling. Genes Dev 14 (2000) 627-644
27. Stegmann T.J. FGF-1: a human growth factor in the induction of neoangiogenesis. Expert Opin Investig Drugs 7 (1998) 2011-2015
28. Ornitz D.M., and Itoh N. Fibroblast growth factors. Genome Biol 2 (2001) 3005.1-3005.12
29. Finklestein S.P., and Plomaritoglou A. Growth Factors (2001), John Wiley & Sons, New York 165-187